Performance evaluation study of ID CORE XT, a high throughput blood group genotyping platform

Area of Science:

• Transfusion Medicine
• Genetics
• Immunology

Background:

• Traditional serological methods for red blood cell antigen identification are being supplemented by molecular techniques.
• Advances in molecular biology enable genetic testing for most blood group antigens, offering enhanced precision.
• The ID CORE XT assay represents a new molecular approach to blood group typing.

Purpose of the Study:

• To validate the performance of the ID CORE XT blood group typing assay.
• To assess the accuracy and reliability of the ID CORE XT for predicting blood group genotypes and phenotypes.
• To compare molecular genotyping results with established serological and molecular methods.

Main Methods:

• 1,000 independent samples from donors, patients, and neonates were collected from Spain and the Netherlands.
• DNA was extracted from blood samples, and genotyping was performed using the ID CORE XT assay.
• Results were compared against well-established serological and molecular typing methods for major and other blood group antigens.

Main Results:

• The ID CORE XT assay exhibited an incorrect call rate of 0% and a 'no call' rate of 0.014%.
• Sensitivity for all phenotypes was 100% compared to serology, with high specificity after resolving minor discrepancies.
• The assay successfully identified common and rare allelic variants, including those of Caucasian origin.

Conclusions:

• The ID CORE XT blood genotyping assay is a reliable and accurate method for predicting clinically relevant blood group antigens.
• The assay meets European Directive standards for performance in extensive sample evaluations.
• Molecular genotyping with ID CORE XT offers a robust alternative to traditional methods for blood group typing.